Investigational Diabetes Drug Shows Strong Results in Phase 3 Trial

Phase 3 trial results indicate that retatrutide, a triple agonist, significantly reduced blood sugar and weight in adults newly diagnosed with type 2 diabetes. Nearly half of the patients achieved normal A1C levels, with up to 90% reaching the target set by the American Diabetes Association. These findings suggest a promising new first-line treatment option for managing type 2 diabetes.